PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen(Baylor College of Medicine), Matthew J. Ellis(Baylor College of Medicine)
Cited by 20
Related Papers
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
|Journal of Clinical Oncology|2001|1.1k